Skip to main content
Equibles
WGS logo

WGS · GeneDx Holdings Corp.

Track WGS — free

Use WGS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about WGS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$78.08 -1.07 (-1.35%) At close · Aug 14
Market Cap
$2.33B
Shares
29.82M

GeneDx Holdings Corp. Earnings Call Transcripts

Every quarterly earnings call for GeneDx Holdings Corp. (WGS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲92.8% $83.23M −$77.58M '22 Q3 22-11-14 ▲6.1% $61.35M −$308.76M '22 Q4 23-03-14 ▼20% $43.14M −$60.99M '23 Q1 23-05-09 ▲34.7% $48.71M −$46.72M '23 Q2 23-08-08 ▼36% $53.30M −$42.29M '23 Q3 23-10-30 ▼6.4% $57.42M −$25.77M '23 Q4 24-02-20 ▲44.7% $62.42M −$20.24M '24 Q1 24-04-29 ▲44.8% $70.51M −$29.17M '24 Q2 24-07-30 ▲44.2% $76.87M −$8.31M '24 Q3 24-10-29 ▲66.6% $95.64M $5.44M '24 Q4 25-02-18 ▲39.6% $87.11M −$6.53M '25 Q1 25-04-30 ▲45.6% $102.69M $10.81M '25 Q2 25-07-29 ▲51.9% $116.74M −$7.63M '25 Q3 25-10-28 ▲26.5% $120.99M −$17.67M '25 Q4 26-02-23 ▲17.4% $102.25M −$63.32M '26 Q1 26-05-04 LATEST ▲11.4% $114.44M −$17.74M '26 Q2 26-08-03
Earnings call
FY26 · Q2
2026-08-03
GeneDx Second Quarter 2026 Earnings Conference Call
Confident tone Mix management (exome vs genome) Volume growth and test record Collections and revenue cycle management
Revenue
$114.44M
▲ 11.4% YoY
Diluted EPS
$-0.60
▼ 266.7% YoY
Gross margin
68.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-04
GeneDx Holdings Corp. Q1 FY2026 Earnings Call
Balanced tone Product Mix Shift to Genome Exome and Genome Volume Growth Reimbursement Dynamics and ARR
Revenue
$102.25M
▲ 17.4% YoY
Diluted EPS
$-2.16
Gross margin
66.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-11
Barclays 28th Annual Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-03-02
TD Cowen 46th Annual Health Care Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-23
GeneDx Holdings Corp. Q4 FY2025 Earnings Call
Confident tone Revenue growth and exome/genome momentum Sales force expansion into new and existing markets GeneDxInfinity data set and competitive moat
Revenue
$120.99M*
▲ 26.5% YoY
Gross margin
69.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-28
GeneDx Holdings Corp. Q3 FY2025 Earnings Call
Confident tone Pediatrician market expansion and sales force build-out Revenue growth and guidance raise NICU and inpatient growth
Revenue
$116.74M
▲ 51.9% YoY
Diluted EPS
$-0.27
Gross margin
72.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
GeneDx Holdings Corp. Q2 FY2025 Earnings Call
Confident tone NICU expansion opportunity State Medicaid coverage and policy landscape Customer experience for non-specialists
Revenue
$102.69M
▲ 45.6% YoY
Diluted EPS
$0.36
Gross margin
69.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-30
GeneDx Holdings Corp. Q1 FY2025 Earnings Call
Confident tone Exome and genome market leadership NICU and inpatient opportunity Fabric Genomics acquisition
Revenue
$87.11M
▲ 39.6% YoY
Diluted EPS
$-0.23
Gross margin
67.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-18
GeneDx Holdings Corp. Q4 FY2024 Earnings Call
Confident tone Exome and Genome Market Leadership NICU and UltraRapid Genome Launch Epic Aura Integration and Customer Experience
Revenue
$95.64M*
▲ 66.6% YoY
Gross margin
69.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-29
GeneDx Holdings Corp. Q3 FY2024 Earnings Call
Confident tone Exome and genome market leadership Profitability and financial discipline Genomic newborn screening
Revenue
$76.87M
▲ 44.2% YoY
Diluted EPS
$-0.31
Gross margin
62.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-30
GeneDx Holdings Corp. Q2 FY2024 Earnings Call
Confident tone Margin expansion and cost per test reduction Exome and genome product mix shift Cash burn reduction and path to profitability
Revenue
$70.51M
▲ 44.8% YoY
Diluted EPS
$-1.10
Gross margin
60.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-29
GeneDx Holdings Corp. Q1 FY2024 Earnings Call
Confident tone Commercial execution and sales force Reimbursement and payer coverage Exome and genome product mix
Revenue
$62.42M
▲ 44.7% YoY
Diluted EPS
$-0.78
Gross margin
59.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-20
GeneDx Holdings Corp. Q4 FY2023 Earnings Call
Confident tone Exome and genome growth Gross margin expansion Cash burn reduction and path to profitability
Revenue
$57.42M*
▼ 6.4% YoY
Gross margin
53.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-30
GeneDx Holdings Corp. Q3 FY2023 Earnings Call
Revenue
$53.30M
▼ 36% YoY
Diluted EPS
$-1.64
Gross margin
47.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
GeneDx Holdings Corp. Q2 FY2023 Earnings Call
Revenue
$48.71M
▲ 34.7% YoY
Diluted EPS
$-1.84
Gross margin
38.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
GeneDx Holdings Corp. Q1 FY2023 Earnings Call
Revenue
$43.14M
▼ 20% YoY
Diluted EPS
$-3.04
Gross margin
35.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-14
GeneDx Holdings Corp. Q4 FY2022 Earnings Call
Revenue
$61.35M*
▲ 6.1% YoY
Gross margin
-26.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
GeneDx Holdings Corp. Q3 FY2022 Earnings Call
Revenue
$83.23M
▲ 92.8% YoY
Diluted EPS
$-6.72
▼ 227.3% YoY
Gross margin
16.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
GeneDx Holdings Corp. Q2 FY2022 Earnings Call
Revenue
$36.17M
▼ 23.1% YoY
Diluted EPS
$-8.38
Gross margin
-81.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
GeneDx Holdings Corp. Q1 FY2022 Earnings Call
Revenue
$53.94M
▼ 16% YoY
Diluted EPS
$-10.38
Gross margin
10.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-14
GeneDx Holdings Corp. Q4 FY2021 Earnings Call
Revenue
$57.80M
▼ 9.6% YoY
Gross margin
-4.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
GeneDx Holdings Corp. Q3 FY2021 Earnings Call
Revenue
$43.18M
▲ 11.8% YoY
Diluted EPS
$5.28
Gross margin
-19.2%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
GeneDx Holdings Corp. Q2 FY2021 Earnings Call
Revenue
$47.02M
▲ 56.2% YoY
Diluted EPS
$-1384.02
Gross margin
-2.5%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–24 of 24 earnings calls
Key facts CIK 1818331 CUSIP 81663L200 13F (30d) 216 filings 211 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)